Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs tricyclic antidepressants

JAMA

Volumn 275, Issue 24, 1996, Pages 1897-1902

  Simon, Gregory E ^a,d,e   VonKorff, Michael ^a,d   Heiligenstein, John H ^b   Revicki, Dennis A ^c   Grothaus, Louis ^a   Katon, Wayne ^d   Wagner, Edward H ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MEDTAP International   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

EID: 0029922652     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.24.1897     Document Type: Article

References (41)

1. Huszonek J, Dewan MJ, Koss M, Hardoby WJ, Isphanai A. Antidepressant side effects and physician prescribing patterns. Ann Clin Psychiatry. 1993;5:7-11.
2. Olfson M, Klerman GL. Trends in prescription of antidepressants by office-based psychiatrists. Am J Psychiatry. 1993;150:571-577.
3. Kramer P. Listening to Prozac. New York, NY: Viking; 1993.
4. Cowley G, Springer K, Leonard EA, Robinson K, Gordon J. The mind: the promise of Prozac. Newsweek. March 26, 1990;115:38.
5. Brown DE, Epperson SE. Behavior feeling good with Prozac: can happiness - and personality - come packaged in a pill? Time. October 11, 1993;142:61.
6. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683-687.
7. Workman E, Short D. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry. 1993; 54:5-12.
8. Greenberg R, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis. 1994;182:547-551.
9. Stokes P. Fluoxetine: a five-year review. Clin Ther. 1993;15:216-243.
10. Montgomery S, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994;9:47-53.
11. Pande A, SaylerME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol. 1993;8:267-269.
12. Simon G, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hasp Psychiatry. 1993;15:399-408.
13. LePen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord. 1994;31:1-18.
14. Jonsson B, Bebbington PE. What price depression: the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164:665-673.
15. Schwarte D, Lellouch J. Explanatory and pragmatic attitudes in clinical trials. J Chronic Dis. 1967;20:637-648.
16. Feinstein A. An additional basic science for clinical medicine, II: the limitations of randomized trials. Ann Intern Med. 1983;99:544-550.
17. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. J Clin Epidemiol. 1995;48:363-373.
18. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull. 1995;31:57-65.
19. Katon W, VonKorff M, Lin E, Bush T, OrmelJ. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30:67-76.
20. Glaser M. Annual Rx survey: Rx sales hit new high. Drug Topics. 1995;139(7):43-48.
21. Olfson M, Pincus HA. Outpatient psychotherapy in the United States, I: volume, costs, and user characteristics. Am J Psychiatry. 1994;151:1281-1288.
22. Sclar D, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther. 1994; 16:715-730.
23. Revicki DA, Brown RE, Palmer W, et al. Modeling the cost-effectiveness of antidepressant treatment in primary care. Pharmacoeconomics. 1995; 8:524-540.
24. Mayfield D,MeLeod G, Hall P. The C AGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131:1121-1123.
25. Spitzer RL, Williams JBW, Gibbon M, First MB. User's Guide for the Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press; 1990.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
27. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
28. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;46:742-747.
29. Derogatis L, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist: a measure of primary symptom dimensions. In: Pichot P, ed. Psychological Measurements in Psychopharmacology: Problems in Psychopharmacology. Basel, Switzerland: Kargerman; 1974:79-110.
30. Ware J, Sherbourne C. The MOS 36-Item Short-Form Health Survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473-483.
31. Ware J, Kosinski M, Keller SD. SF-36 Physical and Mental Component Summary Scales: A User's Manual. Boston, Mass: The Health Institute, New England Medical Center; 1994.
32. Simon G, VonKorff M, Revicki D. Telephone assessment of depression severity. J Psychiatr Res. 1993;27:247-252.
33. Saunders K, Stergachis A, VonKorff M. Group Health Cooperative of Puget Sound. In: Strom B, ed. Pharmacoepidemiology. New York, NY: John Wiley & Sons; 1994.
34. Simon G, Lin EHB, Katon W, et al. Outcomes of 'inadequate' antidepressant treatment in primary care. J Gen Intern Med. 1995;10:663-670.
35. VonKorff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
36. Clark D, VonKorff M, Saunders K, Baluch WM, Simon GE. A Chronic Disease Score with empirically derived weights. Med Care. 1995;33:783-795.
37. Simon G, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52:850-856.
38. Sackett D, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410-1412.
39. Ware J. Linear models for the analysis of longitudinal studies. Am Statistician. 1992;39:95-101.
40. Wolfinger R. SAS Technical Support Document 260: A Tutorial on Muxed Models. Cary, NC: SAS Institute Inc; 1992.
41. Depression Guideline Panel. Depression in Primary Care: Clinical Practice Guideline. Rockville, Md: US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993.